Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel

British Journal of Cancer

Volumn 99, Issue 7, 2008, Pages 1103-1113

  Oikonomopoulou, K ^a,b   Li, L ^c   Zheng, Y ^c   Simon, I ^d   Wolfert, R L ^d   Valik, D ^e   Nekulova, M ^e   Simickova, M ^e   Frgala, T ^e   Diamandis, E P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c Fred Hutchinson Cancer Research Center   (United States)

^d diaDexus Inc   (United States)

^e MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Biomarkers; Human tissue kallikreins; Multiparametric analysis; Ovarian cancer; Prediction of therapy; Serine proteases

Indexed keywords

B7 ANTIGEN; B7 H4 ANTIGEN; BIOLOGICAL MARKER; CA 125 ANTIGEN; CARBOPLATIN; KALLIKREIN; KALLIKREIN 10; KALLIKREIN 11; KALLIKREIN 5; KALLIKREIN 6; KALLIKREIN 7; NEUROPSIN; PACLITAXEL; PROTEIN DERIVATIVE; REGENERATING PROTEIN IV; SPONDIN 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 53049091243     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604630     Document Type: Article

References (60)

1. Adib TR, Henderson S, Perrett C, Hewitt D, Bourmpoulia D, Ledermann J, Boshoff C (2004) Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 90: 686-692
2. Aimes RT, Zijlstra A, Hooper JD, Ogbourne SM, Sit ML, Fuchs S, Gotley DC, Quigley JP, Antalis TM (2003) Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb Haemost 89: 561-572
3. American Cancer Society 2007 Facts and figures 2007: American Cancer Society
4. Bast Jr RC (2003) Status of tumor markers in ovarian cancer screening. J Clin Oncol 21: 200s-205s
5. Borgono CA, Diamandis EP (2004) The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 4: 876-890
6. Borgono CA, Kishi T, Scorilas A, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis EP (2006) Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. Clin Cancer Res 12: 1487-1493
7. Borgono CA, Michael IP, Diamandis EP (2004) Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2: 257-280
8. Bose CK, Mukherjea M (1994) Enzymatic tumour markers in ovarian cancer: a multiparametric study. Cancer Lett 77: 39-43
9. Diamandis EP (2004) Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 3: 367-378
10. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL (2005) Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65: 2162-2169
11. Eguchi S, Copas J (2002) A class of logistic-type discriminant functions. Biometrika 89: 1-22
12. Foekens JA, Diamandis EP, Yu H, Look MP, Meijer-van Gelder ME, van Putten WL, Klijn JG (1999) Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. Br J Cancer 79: 888-894
13. Frenette G, Tremblay RR, Lazure C, Dube JY (1997) Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int J Cancer 71: 897-899
14. Ghosh MC, Grass L, Soosaipillai A, Sotiropoulou G, Diamandis EP (2004) Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biol 25: 193-199
15. Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56: 337-344
16. Hibbs K, Skubitz KM, Pambuccian SE, Casey RC, Burleson KM, Oegema Jr TR, Thiele JJ, Grindle SM, Bliss RL, Skubitz AP (2004) Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 165: 397-414
17. Hoffman BR, Katsaros D, Scorilas A, Diamandis P, Fracchioli S, Rigault de la Longrais IA, Colgan T, Puopolo M, Giardina G, Massobrio M, Diamandis EP (2002) Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. Br J Cancer 87: 763-771
18. Huang CY, Cheng WF, Lee CN, Su YN, Chien SC, Tzeng YL, Hsieh CY, Chen CA (2006) Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Res 26: 4721-4728
19. Ignatenko NA, Zhang H, Watts GS, Skovan BA, Stringer DE, Gerner EW (2004) The chemopreventive agent alpha-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells. Mol Carcinog 39: 221-233
20. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66
21. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast Jr RC (2004) Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10: 3291-3300
22. Luo LY, Diamandis EP, Look MP, Soosaipillai AP, Foekens JA (2002) Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br J Cancer 86: 1790-1796
23. Luo LY, Katsaros D, Scorilas A, Fracchioli S, Piccinno R, Rigault de la Longrais IA, Howarth DJ, Diamandis EP (2001) Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res 7: 2372-2379
24. Magklara A, Scorilas A, Catalona WJ, Diamandis EP (1999) The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem 45: 1960-1966
25. Marsden DE, Friedlander M, Hacker NF (2000) Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol 19: 11-19
26. McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP (2007) Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin Cancer Res 13: 4422-4428
27. McIntosh MW, Pepe MS (2002) Combining several screening tests: optimality of the risk score. Biometrics 58: 657-664
28. Meyer T, Rustin GJ (2000) Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 82: 1535-1538
29. Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Ghosh M, Wasney G, Diamandis EP (2005) Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem 280: 14628-14635
30. Mills GB, Bast Jr RC, Srivastava S (2001) Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst 93: 1437-1439
31. Mitani Y, Oue N, Matsumura S, Yoshida K, Noguchi T, Ito M, Tanaka S, Kuniyasu H, Kamata N, Yasui W (2007) Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene 26: 4383-4393
32. Nguyen HN, Averette HE, Hoskins W, Sevin BU, Penalver M, Steren A (1993) National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer 72: 3007-3011
33. Ni X, Zhang W, Huang KC, Wang Y, Ng SK, Mok SC, Berkowitz RS, Ng SW (2004) Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer 91: 725-731
34. Oikonomopoulou K, Hansen KK, Saifeddine M, Tea I, Blaber M, Blaber SI, Scarisbrick I, Andrade-Gordon P, Cottrell GS, Bunnett NW, Diamandis EP, Hollenberg MD (2006a) Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem 281: 32095-32112
35. Oikonomopoulou K, Michael IP, Scorilas A, Michael IP, Grass L, Soosaipillai A, Rosen B, Murphy J, Diamandis EP (2006b) Kallikreins as markers of disseminated tumour cells in ovarian cancer - a pilot study. Tumour Biol 27: 104-114
36. Pampalakis G, Sotiropoulou G (2007) Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim Biophys Acta 1776: 22-31
37. Petraki CD, Karavana VN, Revelos KI, Luo LY, Diamandis EP (2002) Immunohistochemical localization of human kallikreins 6 and 10 in pancreatic islets. Histochem J 34: 313-322
38. Rai AJ, Zhang Z, Rosenzweig J, Shih IeM, Pham T, Fung ET, Sokoll LJ, Chan DW (2002) Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 126: 1518-1526
39. Ramachandran R, Hollenberg MD (2007) Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol 153(Suppl 1): S263-S282
40. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE (1996) Defining progression of ovarian carcinoma during follow-up according to CA125: a North Thames Ovary Group Study. Ann Oncol 7: 361-364
41. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy Jr J, Pecorelli S (2004) Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. In J Cancer 112: 14-25
42. Shan SJ, Scorilas A, Katsaros D, Rigault de la Longrais I, Massobrio M, Diamandis EP (2006) Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. Clin Chem 52: 1879-1886
43. Shaw JL, Diamandis EP (2007) Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 53: 1423-1432
44. Shih IeM, Salani R, Fiegl M, Wang TL, Soosaipillai A, Marth C, Müller-Holzner E, Gastl G, Zhang Z, Diamandis EP (2007) Ovarian cancer specific kallikrein profile in effusions. Gynecol Oncol 105: 501-507
45. Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast Jr RC, Gershenson DM, Schmandt R (2003) Over-expression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 90: 44-50
46. Simon I, Katsaros D, Rigault de la Longrais I, Massobrio M, Scorilas A, Kim NW, Sarno MJ, Wolfert RL, Diamandis EP (2007a) B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol 106: 334-341
47. Simon I, Liu Y, Krall KL, Urban N, Wolfert RL, Kim NW, McIntosh MW (2007b) Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol 106: 112-118
48. Stephan C, Jung K, Diamandis EP, Rittenhouse HG, Lein M, Loening SA (2002) Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology 59: 2-8
49. Takayama TK, McMullen BA, Nelson PS, Matsumura M, Fujikawa K (2001) Characterization of hK4 (Prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 40: 15341-15348
50. Tanimoto H, Underwood LJ, Shigemasa K, Yan Yan MS, Clarke J, Parmley TH, O'Brien TJ (1999) The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer 86: 2074-2082
51. Tuxen MK, Soletormos G, Dombernowsky P (1995) Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 21: 215-245
52. Van der Berg ME, Lammes FB, van Putten WL, Stoter G (1988) Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol 30: 307-312
53. van der Merwe DE, Oikonomopoulou K, Marshall J, Diamandis EP (2007) Mass spectrometry: uncovering the cancer proteome for diagnostics. Adv Cancer Res 96: 23-50
54. Xi Z, Kaern J, Davidson B, Klokk TI, Risberg B, Tropé C, Saatcioglu F (2004) Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. Gynecol Oncol 94: 80-85
55. Yoi OO, Seldin DC, Spragg J, Pinkus GS, Austen KF (1979) Sequential cleavage of proinsulin by human pancreatic kallikrein and a human pancreatic kininase. Proc Natl Acad Sci USA 76: 3612-3616
56. Yoon H, Laxmikanthan G, Lee J, Blaber SI, Rodriguez A, Kogot JM, Scarisbrick IA, Blaber M (2007) Activation profiles and regulatory cascades of the human kallikrein-related peptidases. J Biol Chem 282: 31852-31864
57. Yousef GM, Polymeris ME, Yacoub GM, Scorilas A, Soosaipillai A, Popalis C, Fracchioli S, Katsaros D, Diamandis EP (2003) Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 63: 2223- 2227
58. Zanotti KM, Kennedy AW (1999) Screening for gynecologic cancer. Med Clin North Am 83: 1467-1487
59. Zhang Z, Bast Jr RC, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW (2004) Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64: 5882-5890
60. Zheng Y, Cai T, Feng Z (2006) Application of the time-dependent ROC curves for prognostic accuracy with multiple biomarkers. Biometrics 62: 279-287